Unique Distal Enhancers Linked to the Mouse Tnfsf11 Gene Direct Tissue-Specific and Inflammation-Induced Expression of RANKL.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Endocrinology

• Publication date

  2016-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1210/en.2015-1788PMID 26646205PMCID PMC4733116
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Deletion of the Distal Tnfsf11 RL‐D2 Enhancer That Contributes to PTH‐Mediated RANKL Expression in Osteoblast Lineage Cells Results in a High Bone Mass Phenotype in Mice

  2016cited by this paper
• The selection and function of cell type-specific enhancers

  2015cited by this paper
• A DNA Segment Spanning the Mouse Tnfsf11 Transcription Unit and Its Upstream Regulatory Domain Rescues the Pleiotropic Biologic Phenotype of the RANKL Null Mouse

  2015cited by this paper
• RANKL expressed on synovial fibroblasts is primarily responsible for bone erosions during joint inflammation

  2015cited by this paper
• Correction: Stat3 Activation Is Responsible for IL-6–Dependent T Cell Proliferation through Preventing Apoptosis: Generation and Characterization of T Cell–Specific Stat3-Deficient Mice

  2015cited by this paper
• Lymphocytes in atherosclerosis.

  2015cited by this paper
• Transcriptional Regulation of the Human TNFSF11 Gene in T Cells via a Cell Type‐Selective Set of Distal Enhancers

  2015cited by this paper
• T Cell–Expressed CD40L Potentiates the Bone Anabolic Activity of Intermittent PTH Treatment

  2015cited by this paper
• The immune system, bone and RANKL.

  2014cited by this paper
• T-cells and B-cells in osteoporosis

  2014cited by this paper
• The osteoblast to osteocyte transition: epigenetic changes and response to the vitamin D3 hormone.

  2014cited by this paper
• Osteocyte-derived RANKL is a critical mediator of the increased bone resorption caused by dietary calcium deficiency.

  2014cited by this paper
• Autoimmune arthritis: the interface between the immune system and joints.

  2012cited by this paper
• RANKL Induces Organized Lymph Node Growth by Stromal Cell Proliferation

  2012cited by this paper
• Osteocyte RANKL: New insights into the control of bone remodeling

  2012cited by this paper
• Receptor Activator of Nuclear Factor κB Ligand (RANKL) Protein Expression by B Lymphocytes Contributes to Ovariectomy-induced Bone Loss*

  2012cited by this paper
• The RANKL distal control region is required for the increase in RANKL expression, but not the bone loss, associated with hyperparathyroidism or lactation in adult mice.

  2012cited by this paper
• Sustained RANKL response to parathyroid hormone in oncostatin M receptor‐deficient osteoblasts converts anabolic treatment to a catabolic effect in vivo

  2012cited by this paper
• The mouse RANKL gene locus is defined by a broad pattern of histone H4 acetylation and regulated through distinct distal enhancers

  2011cited by this paper
• [RANKL signal and osteoimmunology].

  2011cited by this paper
• Recent Advances on the Role of Cytokines in Atherosclerosis

  2011cited by this paper
• Mouse Rankl Expression Is Regulated in T Cells by c-Fos through a Cluster of Distal Regulatory Enhancers Designated the T Cell Control Region*

  2011cited by this paper
• Matrix-embedded cells control osteoclast formation

  2011cited by this paper
• Evidence for osteocyte regulation of bone homeostasis through RANKL expression

  2011cited by this paper
• Increased PTHrP and decreased estrogens alter bone turnover but do not reproduce the full effects of lactation on the skeleton.

  2010cited by this paper
• gp130 signaling in bone cell biology: multiple roles revealed by analysis of genetically altered mice.

  2009cited by this paper
• Central control of fever and female body temperature by RANKL/RANK

  2009cited by this paper
• A novel distal enhancer mediates cytokine induction of mouse RANKl gene expression.

  2009cited by this paper
• An enhancer 20 kilobases upstream of the human receptor activator of nuclear factor-kappaB ligand gene mediates dominant activation by 1,25-dihydroxyvitamin D3.

  2008cited by this paper
• Osteoclast size is controlled by Fra-2 through LIF/LIF-receptor signalling and hypoxia

  2008cited by this paper
• Targeted deletion of a distant transcriptional enhancer of the receptor activator of nuclear factor-kappaB ligand gene reduces bone remodeling and increases bone mass.

  2008cited by this paper
• Weaning triggers a decrease in receptor activator of nuclear factor-kappaB ligand expression, widespread osteoclast apoptosis, and rapid recovery of bone mass after lactation in mice.

  2007cited by this paper
• Transcriptional control of receptor activator of nuclear factor-kappaB ligand by the protein kinase A activator forskolin and the transmembrane glycoprotein 130-activating cytokine, oncostatin M, is exerted through multiple distal enhancers.

  2007cited by this paper
• The Immune Response Is Involved in Atherosclerotic Plaque Calcification: Could the RANKL/RANK/OPG System Be a Marker of Plaque Instability?

  2007cited by this paper
• Multiple enhancer regions located at significant distances upstream of the transcriptional start site mediate RANKL gene expression in response to 1,25-dihydroxyvitamin D3.

  2007cited by this paper
• IL-6-gp130-STAT3 in T cells directs the development of IL-17+ Th with a minimum effect on that of Treg in the steady state.

  2007cited by this paper
• Activation of Receptor Activator of NF-κB Ligand Gene Expression by 1,25-Dihydroxyvitamin D3 Is Mediated through Multiple Long-Range Enhancers

  2006cited by this paper
• Enhanced T-Cell Expression of RANK Ligand in Acute Coronary Syndrome: Possible Role in Plaque Destabilization

  2006cited by this paper
• Parathyroid Hormone Controls Receptor Activator of NF-κB Ligand Gene Expression via a Distant Transcriptional Enhancer

  2006cited by this paper
• Inflammatory bone destruction and osteoimmunology.

  2005cited by this paper
• IL-6 is not required for parathyroid hormone stimulation of RANKL expression, osteoclast formation, and bone loss in mice.

  2005cited by this paper
• Interleukin‐11 Receptor Signaling Is Required for Normal Bone Remodeling

  2005cited by this paper
• Expression of membrane-bound and soluble receptor activator of NF-kappaB ligand (RANKL) in human T cells.

  2004cited by this paper
• The role of the interleukin-6 family of cytokines in inflammatory arthritis and bone turnover.

  2003cited by this paper
• IL-6, Leukemia Inhibitory Factor, and Oncostatin M Stimulate Bone Resorption and Regulate the Expression of Receptor Activator of NF-κB Ligand, Osteoprotegerin, and Receptor Activator of NF-κB in Mouse Calvariae1

  2002cited by this paper
• Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

  2001cited by this paper
• The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development.

  2000cited by this paper
• Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene.

  2000cited by this paper
• Regulation of Peripheral Lymph Node Genesis by the Tumor Necrosis Factor Family Member Trance

  2000cited by this paper
• Prostaglandin E2 Induces Expression of Receptor Activator of Nuclear Factor–κB Ligand/Osteoprotegrin Ligand on Pre‐B Cells: Implications for Accelerated Osteoclastogenesis in Estrogen Deficiency

  2000cited by this paper
• STAT3 Activation in Stromal/Osteoblastic Cells Is Required for Induction of the Receptor Activator of NF-κB Ligand and Stimulation of Osteoclastogenesis by gp130-utilizing Cytokines or Interleukin-1 but Not 1,25-Dihydroxyvitamin D3 or Parathyroid Hormone*

  1999cited by this paper
• OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

  1999cited by this paper
• Evidence for a role of a tumor necrosis factor-alpha (TNF-alpha)-converting enzyme-like protease in shedding of TRANCE, a TNF family member involved in osteoclastogenesis and dendritic cell survival.

  1999cited by this paper
• Promoter structure of mouse RANKL/TRANCE/OPGL/ODF gene.

  1999cited by this paper
• Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival*

  1999cited by this paper
• Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.

  1998cited by this paper
• Transforming Growth Factor-β Stimulates the Production of Osteoprotegerin/Osteoclastogenesis Inhibitory Factor by Bone Marrow Stromal Cells*

  1998cited by this paper
• Distribution and expression of mRNAs for the proto-oncogenes c-fos and c-jun in bone cells in vivo.

  1998cited by this paper
• Stat3 activation is responsible for IL-6-dependent T cell proliferation through preventing apoptosis: generation and characterization of T cell-specific Stat3-deficient mice.

  1998cited by this paper
• Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.

  1998cited by this paper
• Regulation of interleukin-6, osteoclastogenesis, and bone mass by androgens. The role of the androgen receptor.

  1995cited by this paper
• Interleukin‐6 deficient mice are protected from bone loss caused by estrogen depletion.

  1994cited by this paper
• c-Fos: a key regulator of osteoclast-macrophage lineage determination and bone remodeling.

  1994cited by this paper
• The bone marrow-derived stromal cell lines MC3T3-G2/PA6 and ST2 support osteoclast-like cell differentiation in cocultures with mouse spleen cells.

  1989cited by this paper
• Research Paper Mediators of Inflammation, 7, 347–353 (1998)

  year unknowncited by this paper
• Printed in U.S.A. Copyright © 1999 by The Endocrine Society A Role for Interleukin-6 in Parathyroid Hormone- Induced Bone Resorption in Vivo*

  year unknowncited by this paper
• Printed in U.S.A. Copyright © 1999 by The Endocrine Society Parathyroid Hormone Stimulates TRANCE and Inhibits Osteoprotegerin Messenger Ribonucleic Acid Expression in Murine Bone Marrow Cultures: Correlation with

  year unknowncited by this paper

• Tissue expression and promoter activity analysis of the porcine TNFSF11 gene.

  2024cites this paper
• The neutrophil–osteogenic cell axis promotes bone destruction in periodontitis

  2024cites this paper
• ROLE OF RANKL SIGNALING IN BONE HOMEOSTASIS.

  2024cites this paper
• Genomically anchored vitamin D receptor mediates an abundance of bioprotective actions elicited by its 1,25-dihydroxyvitamin D hormonal ligand.

  2023cites this paper
• Identification of an intronic enhancer regulating RANKL expression in osteocytic cells

  2023cites this paper
• ETS1 governs pathological tissue-remodeling programs in disease-associated fibroblasts

  2022cites this paper
• Single-Cell Transcriptomics Reveals the Complexity of the Tumor Microenvironment of Treatment-Naive Osteosarcoma

  2021cites this paper
• Vitamin D Receptor Mediates a Myriad of Biological Actions Dependent on Its 1,25‐Dihydroxyvitamin D Ligand: Distinct Regulatory Themes Revealed by Induction of Klotho and Fibroblast Growth Factor‐23

  2020cites this paper
• Vitamin D and its analogs

  2020cites this paper
• The molecular actions of parathyroid hormone/parathyroid hormone–related protein receptor type 1 and their implications

  2020cites this paper
• Vitamin D gene regulation

  2020cites this paper
• New developments in our understanding of vitamin metabolism, action and treatment.

  2019cites this paper
• Activation of Shc1 Allows Oncostatin M to Induce RANKL and Osteoclast Formation More Effectively Than Leukemia Inhibitory Factor

  2019cites this paper
• Vitamin D Biochemistry and Physiology

  2018cites this paper
• Extraskeletal Effects of Vitamin D

  2018cites this paper
• Switched memory B cells promote alveolar bone damage during periodontitis: An adoptive transfer experiment

  2018cites this paper
• GATA4 represses RANKL in osteoblasts via multiple long-range enhancers to regulate osteoclast differentiation.

  2018cites this paper
• Improved RANKL expression and osteoclastogenesis induction of CD27+CD38- memory B cells: A link between B cells and alveolar bone damage in periodontitis.

  2018cites this paper
• Genome-Wide Perspectives on Vitamin D Receptor–Mediated Control of Gene Expression in Target Cells

  2018cites this paper
• The vitamin D receptor: contemporary genomic approaches reveal new basic and translational insights.

  2017cites this paper
• Parathyroid Hormone Signaling in Osteocytes

  2017cites this paper
• Deletion of a Distal RANKL Gene Enhancer Delays Progression of Atherosclerotic Plaque Calcification in Hypercholesterolemic Mice

  2017influential citation
• Biology and Mechanisms of Action of the Vitamin D Hormone.

  2017cites this paper
• Absence of the Vitamin D Receptor Inhibits Atherosclerotic Plaque Calcification in Female Hypercholesterolemic Mice

  2017cites this paper
• A Novel Distal Enhancer Mediates Inflammation‐, PTH‐, and Early Onset Murine Kidney Disease‐Induced Expression of the Mouse Fgf23 Gene

  2017cites this paper